Rifabutin for Mycobacterium abscessus lung infection
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests whether an antibiotic called rifabutin works better for treating a difficult lung infection (Mycobacterium abscessus) that resists a common antibiotic. You may qualify if you've been diagnosed with this infection and your lab tests show it can resist clarithromycin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed diagnosis of Mycobacterium abscessus lung infection
- Lab tests show your infection has inducible clarithromycin resistance (meaning it resists a standard antibiotic in a specific way)
- Your infection is active on chest imaging (X-ray or CT scan)
- You are well enough to start antibiotic treatment
- You are not pregnant or breastfeeding, and can take rifabutin without severe allergic reactions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of antibiotics (Arm D) against the standard treatment for people with a difficult-to-treat lung infection called Mycobacterium abscessus. It is for adults and teens aged 12 and older, including those with cystic fibrosis.
This study tests whether a new antibiotic, Contezolid, can quickly reduce the amount of Mycobacterium abscessus in your lungs. It may be a treatment option if you have had a positive sputum test in the past 6 months.
This study tests an investigational medication called epetraborole for people with a chronic lung infection caused by Mycobacterium abscessus bacteria. You may be able to join if your infection is stable enough to delay standard treatment and you have symptoms like cough, fatigue, or weight loss.
This study tests if a drug called sitafloxacin can quickly kill mycobacterium abscessus bacteria in the lungs. It may help people with this hard-to-treat infection find a more effective treatment.
This study looks for the best way to treat Mycobacterium abscessus (MABS), a difficult lung infection. You may join a treatment group, or first join an observation group and possibly move into treatment later if you meet the criteria.
This trial tests whether you can take a shorter course of standard treatment for drug-sensitive pulmonary (lung) tuberculosis by using a higher dose of rifampicin. It may help some people finish treatment sooner, while doctors track how well the infection clears.
Hear when a new Mycobacterium Abscessus Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.